Finn Wislöff - Concepedia

Author

Finn Wislöff

Oslo University Hospital

Also Known As

A Larsen, D. Cohen, F WISLOFF, F Wisloff, F Wislöff, F Wisløff, F. WISLOFF, F. WISLØFF, F. WISLøFF, F. Wislöff

159

Publications

Citations

H-Index

Concepts

All Affiliations

Oslo University Hospital University of Oslo Lund University Sjukhuset i Lidköping University of Aberdeen

About

Finn Wislöff is an author at Oslo University Hospital specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	23	1.7K
2	Health Sciences	9	9	361
3	Allergy	3	3	82
4	Public Health	2	2	478
5	Biostatistics	1	1	454

Finn Wislöff

Publications

Citations

H-Index

Page 1

	Year	Citations
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) Guido Finazzi, Roberto Marchioli, Vincenzo Brancaccio, Journal of Thrombosis and Haemostasis ThrombosisRandomized Clinical TrialCardiovascular DiseaseBlood PlateletHematology	2005	582
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life Eva Hellström‐Lindberg, Nina Gulbrandsen, Greger Lindberg, British Journal of Haematology Hematological MalignancyImmunohematologyLaboratory HematologyBone Marrow FailureValidated Decision Model	2003	454
Guidelines on the diagnosis and management of multiple myeloma 2005 Alastair G. Smith, Finn Wislöff, Diana Samson British Journal of Haematology	2005	314
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Stig Lenhoff, Martin Hjorth, Erik Holmberg, PubMed	2000	312
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma Anders Waage, Peter Gimsing, Peter Fayers, Blood	2010	231
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study Monica Galli, Giovanna Borrelli, E. Jacobsen, Blood	2007	170
Measurement of health‐related quality of life in multiple myeloma Finn Wislöff, Sverre Eika, Erik Hippe, British Journal of Haematology	1996	124
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences Nina Gulbrandsen, Marianne Jensen Hjermstad, Finn Wislöff European Journal Of Haematology	2004	119
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial Peter Gimsing, Kristina Carlson, Ingemar Turesson, The Lancet Oncology Bone DiseaseHematological MalignancyBone HealthMedicineClinical Trials	2010	117
Responsiveness and minimal important score differences in quality‐of‐life questionnaires: a comparison of the EORTC QLQ‐C30 cancer‐specific questionnaire to the generic utility questionnaires EQ‐5D and 15D in patients with multiple myeloma Ann Kristin Kvam, Peter Fayers, Finn Wislöff European Journal Of Haematology	2011	116

Page 1